1. This article discusses the potential of exploiting bacterial glycosylation machineries for the synthesis of a Lewis antigen-containing glycoprotein.
2. The article outlines a mixed approach consisting of in vivo and in vitro steps for the synthesis of this glycoprotein, using glycosyltransferases from Haemophilus influenzae, Escherichia coli, Campylobacter jejuni, and Helicobacter pylori.
3. Mass spectrometry techniques were used to confirm the structure of the glycan, demonstrating that bacterial enzymes can be exploited for the production of glycoproteins carrying glycans present in human cells for potential therapeutic applications.
This article is generally reliable and trustworthy as it provides an overview of how bacterial glycosylation machineries can be exploited for the synthesis of a Lewis antigen-containing glycoprotein with potential therapeutic applications. The authors provide detailed information on their mixed approach consisting of in vivo and in vitro steps for the synthesis of this glycoprotein, using various bacterial enzymes from Haemophilus influenzae, Escherichia coli, Campylobacter jejuni, and Helicobacter pylori. Furthermore, mass spectrometry techniques are used to confirm the structure of the glycan produced by this method.
The article does not appear to have any major biases or one-sided reporting as it presents both sides equally and does not make any unsupported claims or omit any points of consideration. It also does not contain any promotional content or partiality towards either side. Additionally, possible risks associated with this method are noted throughout the article.
In conclusion, this article is generally reliable and trustworthy as it provides an overview on how bacterial enzymes can be exploited for the production of a Lewis antigen-containing glycoprotein with potential therapeutic applications without making any unsupported claims or omitting any points of consideration.